Co-Diagnostics (CODX) Misses Q2 EPS by 16c

Co-Diagnostics (NASDAQ: CODX) reported Q2 EPS of $0.43, $0.16 worse than the analyst estimate of $0.59. Revenue for the quarter came in at $24.04 million versus the consensus estimate of $26.45 million.

For earnings history and earnings-related data on Co-Diagnostics (CODX) click here.

You May Also Be Interested In

• KB Home (KBH) Tops Q3 EPS by 16c
• Talos Energy closes $420M Gulf of America deepwater asset deal
• AnaptysBio, Inc. (ANAB) Tops Q2 EPS by 524c